Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described. In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic symptoms of depression have never been investigated. Our objective was to determine the prevalence and to describe features of depression in a large cohort of mastocytosis patients (n = 288) and to investigate the therapeutic impact of the protein kinase inhibitor masitinib in depression symptoms. The description of depression was based on the analysis of a database with Hamilton scores using Principal Component Analysis (PCA). Efficacy of masitinib therapy was evaluated using non parametric Wilcoxon test for paired data within a three months period (n = 35). Our results show that patients with indolent mastocytosis present an elevated prevalence of depression (64%). Depression was moderate in 56% but severe in 8% of cases. Core symptoms (such as psychic anxiety, depressed mood, work and interests) characterized depression in mastocytosis patients. Masitinib therapy was associated with significant improvement (67% of the cases) of overall depression, with 75% of recovery cases. Global Quality of Life slightly improved after masitinib therapy and did not predicted depression improvement. In conclusion, depression is very frequent in mastocytosis patients and masitinib therapy is associated with the reduction its psychic experiences. We conclude that depression in mastocytosis may originate from processes related to mast cells activation. Masitinib could therefore be a useful treatment for mastocytosis patients with depression and anxiety symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606 · cited 1×
“In addition, the regulation of emotional behavior is due to the connections of the nuclei of thalamus with other limbic system structures [56,57].”
BackgroundTwenty years of research on cytokine-induced sickness behavior
Dantzer, R., & Kelley, K. W. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.09.006 · Cited by 1,420
Shafer, A. B. (2006) · Journal of Clinical Psychology · doi:10.1002/jclp.20213 · Cited by 837
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 1×
“Based on organ dysfunction, systemic mastocytosis is divided into indolent and aggressive disease [1,4,5].”
BackgroundSelf-citationMasitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421 · cited 2×
“Thus, masitinib may have a cytotoxic effect and may reduce tumor burden in patients bearing pediatric’s type mutations or wild type c-kit [16].”
BackgroundSelf-citationBodemer, C., Hermine, O., Palmérini, F., Yang, Y., Grandpeix-Guyodo, C., Leventhal, P. S., Hadj-Rabia, S., Nasca, L., Georgin-Lavialle, S., Cohen-Akenine, A., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.281 · Cited by 397
Self-citationMixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type
Brintzenhofe-Szoc, K. M., Levin, T. T., Li, Y., Kissane, D. W., & Zabora, J. R. (2009) · Psychosomatics · doi:10.1176/appi.psy.50.4.383 · Cited by 364
Esposito, P., Chandler, N., Kandere, K., Basu, S., Jacobson, S., Connolly, R., Tutor, D., & Theoharides, T. C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038497 · Cited by 252
Theoharides, T. C., Spanos, C., Pang, X., Alferes, L., Ligris, K., Letourneau, R., Rozniecki, J. J., Webster, E., & Chrousos, G. P. (1995) · Endocrinology · doi:10.1210/endo.136.12.7588332 · Cited by 214
The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions
Bienenstock, J., Tomioka, M., Matsuda, H., Stead, R. H., Quinonez, G., Simon, G. T., Coughlin, M. D., & Denburg, J. A. (2009) · International Archives of Allergy and Applied Immunology · doi:10.1159/000234197 · Cited by 193
Cited by
An Inflammation-Centric View of Neurological Disease: Beyond the Neuron
Skaper, S. D., Facci, L., Zusso, M., & Giusti, P. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00072 · Cited by 457
Pardanani, A. (2013) · Blood · doi:10.1182/blood-2013-01-453183 · Cited by 101
“Masitinib is an investigational TKI with in vitro inhibitory activity against wild type KIT and juxtamembrane activating mutations of KIT but not KITD816V, that improves flushing, pruritus and depression in mastocytosis patients; it remains unclear however as to what advantage, if any, this drug has over imatinib.(26,…”
BackgroundPatient perceptions in mast cell disorders
Jennings, S. V., Slee, V. M., Zack, R. M., Verstovsek, S., George, T. I., Shi, H., Lee, P., & Castells, M. C. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.006 · Cited by 53
Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin
Fuchs, D., Kilbertus, A., Kofler, K., von Bubnoff, N., Shoumariyeh, K., Zanotti, R., Bonadonna, P., Scaffidi, L., Doubek, M., Elberink, H. O., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.12.022 · Cited by 30
Self-citationPsychological functioning and quality of life in patients with mastocytosis
Vermeiren, M. R., Kranenburg, L. W., van Daele, P. L. A., Gerth van Wijk, R., & Hermans, M. A. W. (2020) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2019.12.020 · Cited by 21
Metadata
- Authors
- Moura, D. S., Sultan, S., Georgin-Lavialle, S., Pillet, N., Montestruc, F., Gineste, P., Barete, S., Damaj, G., Moussy, A., Lortholary, O., & Hermine, O.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-10-21
- Volume
- 6
- Issue
- 10
- Pages
- e26375
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2091559082
- Cited by
- 74
- References
- 11
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy. https://app.cochat.ai/papers/10.1371/journal.pone.0026375
- The paper
- Moura, D. S., Sultan, S., Georgin-Lavialle, S., Pillet, N., Montestruc, F., Gineste, P., Barete, S., Damaj, G., Moussy, A., Lortholary, O., & Hermine, O. (2011). Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy. PLoS ONE. https://doi.org/10.1371/journal.pone.0026375
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.